New Individualized Therapy Trial for Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of imatinib mesylate in
combination with panitumumab for the treatment of stage IV colorectal cancer that has spread
to the liver. It will also assess the whether imatinib mesylate, either alone or in
combination with panitumumab, is effective in treating this type of cancer. In addition, the
study will evaluate the feasibility of a predefined lab score and whether it can predict
which patients will respond to treatment with imatinib mesylate.